GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Cyclically Adjusted PB Ratio

Medivir AB (Medivir AB) Cyclically Adjusted PB Ratio : (As of May. 01, 2024)


View and export this data going back to . Start your Free Trial

What is Medivir AB Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medivir AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Medivir AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Cyclically Adjusted PB Ratio Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.24 0.42 0.36 0.14

Medivir AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.30 0.27 0.27 0.14

Competitive Comparison of Medivir AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PB Ratio falls into.



Medivir AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Medivir AB's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Medivir AB's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.381/130.9575*130.9575
=0.381

Current CPI (Dec. 2023) = 130.9575.

Medivir AB Quarterly Data

Book Value per Share CPI Adj_Book
201403 4.675 99.788 6.135
201406 5.776 100.432 7.532
201409 6.801 100.161 8.892
201412 6.852 100.225 8.953
201503 5.182 99.950 6.790
201506 5.585 99.995 7.314
201509 5.482 100.228 7.163
201512 5.245 100.276 6.850
201603 5.220 100.751 6.785
201606 5.096 101.019 6.606
201609 4.743 101.138 6.141
201612 5.765 102.022 7.400
201703 3.601 102.022 4.622
201706 3.263 102.752 4.159
201709 3.130 103.279 3.969
201712 2.487 103.793 3.138
201803 2.405 103.962 3.030
201806 1.897 104.875 2.369
201809 1.945 105.679 2.410
201812 1.152 105.912 1.424
201903 0.916 105.886 1.133
201906 0.860 106.742 1.055
201909 0.754 107.214 0.921
201912 0.661 107.766 0.803
202003 0.553 106.563 0.680
202006 0.538 107.498 0.655
202009 0.584 107.635 0.711
202012 0.574 108.296 0.694
202103 0.703 108.360 0.850
202106 0.679 108.928 0.816
202109 0.633 110.338 0.751
202112 0.555 112.486 0.646
202203 0.466 114.825 0.531
202206 0.403 118.384 0.446
202209 0.346 122.296 0.371
202212 0.333 126.365 0.345
202303 0.298 127.042 0.307
202306 0.246 129.407 0.249
202309 0.202 130.224 0.203
202312 0.381 130.958 0.381

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medivir AB  (OTCPK:MVRBF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Medivir AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Medivir AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (Medivir AB) Business Description

Industry
Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.